Local administration of granulocyte macrophage colony-stimulating factor induces local accumulation of dendritic cells and antigen-specific CD8+ T cells and enhances dendritic cell cross-presentation

Vaccine

Volumn 33, Issue 13, 2015, Pages 1549-1555

  Lee, Sung Jong ^a,b   Song, Liwen ^a,c,d,e   Yang, Ming Chieh ^a,f   Mao, Chih Ping ^a   Yang, Benjamin ^a   Yang, Andrew ^a   Jeang, Jessica ^a   Peng, Shiwen ^a   Wu, T C ^a   Hung, Chien Fu ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b The Catholic University of Korea   (South Korea)

^c FUDAN UNIVERSITY   (China)

^d TENTH PEOPLE S HOSPITAL OF TONGJI UNIVERSITY   (China)

^e SHANGHAI INSTITUTE OF PLANNED PARENTHOOD RESEARCH   (China)

^f KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

CRT E7; Dendritic cell; GM CSF; Immunotherapy

Indexed keywords

DNA VACCINE; HUMAN PAPILLOMAVIRUS TYPE 16 E7 CALRETICULIN VACCINE; PLASMID DNA; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TETRAMER; UNCLASSIFIED DRUG; WART VIRUS VACCINE; CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CONTROL; CANCER IMMUNIZATION; CD8+ T LYMPHOCYTE; CELL MATURATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CROSS PRESENTATION; DENDRITIC CELL; DNA IMMUNIZATION; FEMALE; FLOW CYTOMETRY; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INFECTION CONTROL; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VOLUME; VAGINA TUMOR; ANIMAL; ANTIGEN PRESENTING CELL; C57BL MOUSE; IMMUNOLOGY; IMMUNOTHERAPY; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVAGINAL DRUG ADMINISTRATION; MULTIMODALITY CANCER THERAPY; UTERINE CERVICAL NEOPLASMS; VACCINATION; VAGINAL NEOPLASMS;

ADMINISTRATION, INTRAVAGINAL; ANIMALS; ANTIGEN-PRESENTING CELLS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; COMBINED MODALITY THERAPY; CROSS-PRIMING; DENDRITIC CELLS; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNOTHERAPY; INJECTIONS, INTRAMUSCULAR; MICE; MICE, INBRED C57BL; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINATION; VAGINAL NEOPLASMS;

EID: 84924988121     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.02.019     Document Type: Article

References (21)

1. Chaturvedi A.K. Beyond cervical cancer: burden of other HPV-related cancers among men and women. J Adolesc Health 2010, 46:S20-S26.
2. Armarnik S., Sheiner E., Piura B., Meirovitz M., Zlotnik A., Levy A. Obstetric outcome following cervical conization. Arch Gynecol Obstet 2011, 283:765-769.
3. Cardosi R.J., Bomalaski J.J., Hoffman M.S. Diagnosis and management of vulvar and vaginal intraepithelial neoplasia. Obstet Gynecol Clin North Am 2001, 28:685-702.
4. Abbasakoor F., Boulos P.B. Anal intraepithelial neoplasia. Br J Surg 2005, 92:277-290.
5. Su J.H., Wu A., Scotney E., Ma B., Monie A., Hung C.F., et al. Immunotherapy for cervical cancer: research status and clinical potential. BioDrugs 2010, 24:109-129.
6. Cheng W.F., Hung C.F., Chai C.Y., Hsu K.F., He L., Ling M., et al. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest 2001, 108:669-678.
7. Peng S., Lyford-Pike S., Akpeng B., Wu A., Hung C.F., Hannaman D., et al. Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine. Cancer Immunol Immunother 2013, 62:171-182.
8. Chuang C.M., Monie A., Hung C.F., Wu T.C. Treatment with imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination. J Biomed Sci 2010, 17:32.
9. Trimble C.L., Peng S., Kos F., Gravitt P., Viscidi R., Sugar E., et al. A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clin Cancer Res 2009, 15:361-367.
10. Trimble C.L., Clark R.A., Thoburn C., Hanson N.C., Tassello J., Frosina D., et al. Human papillomavirus 16-associated cervical intraepithelial neoplasia in humans excludes CD8 T cells from dysplastic epithelium. J Immunol 2010, 185:7107-7114.
11. Daayana S., Elkord E., Winters U., Pawlita M., Roden R., Stern P.L., et al. Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia. Br J Cancer 2010, 102:1129-1136.
12. Dranoff G., Jaffee E., Lazenby A., Golumbek P., Levitsky H., Brose K., et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 1993, 90:3539-3543.
13. Han S., Song Y., Lee Y.H., Lee Y.R., Lee C.K., Cho K., et al. Macrophage-colony stimulating factor enhances MHC-restricted presentation of exogenous antigen in dendritic cells. Cytokine 2005, 32:187-193.
14. Mach N., Gillessen S., Wilson S.B., Sheehan C., Mihm M., Dranoff G. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. Cancer Res 2000, 60:3239-3246.
15. Spitler L.E., Grossbard M.L., Ernstoff M.S., Silver G., Jacobs M., Hayes F.A., et al. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol 2000, 18:1614-1621.
16. Lin K.Y., Guarnieri F.G., Staveley-O'Carroll K.F., Levitsky H.I., August J.T., Pardoll D.M., et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996, 56:21-26.
17. Wang T.L., Ling M., Shih I.M., Pham T., Pai S.I., Lu Z., et al. Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity. Gene Ther 2000, 7:726-733.
18. Soong R.S., Song L., Trieu J., Knoff J., He L., Tsai Y.C., et al. Toll like receptor agonist imiquimod facilitates antigen-specific CD8+ T cell accumulation in the genital tract leading to tumor control through interferon-gamma. Clin Cancer Res 2014, 20:5456-5467.
19. Groom J.R., Luster A.D. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol 2011, 89:207-215.
20. Kurbacher C.M., Kurbacher J.A., Cramer E.M., Rhiem K., Mallman P.K., Reichelt R., et al. Continuous low-dose GM-CSF as salvage therapy in refractory recurrent breast or female genital tract carcinoma. Oncology (Williston Park) 2005, 19:23-26.
21. Hubert P., Doyen J., Capelle X., Arafa M., Renoux V., Bisig B., et al. Local applications of GM-CSF induce the recruitment of immune cells in cervical low-grade squamous intraepithelial lesions. Am J Reprod Immunol 2010, 64:126-136.